Whalesbook
Strong Q4 FY25 Performance Sets Stage
CARE Ratings reported robust financial performance for the quarter ending March 31, 2025 (Q4 FY25), with Profit After Tax (PAT) rising 76.4% year-on-year to ₹43.4 crore. Revenue from operations increased by 21.8% year-on-year to ₹109.7 crore during the same period.
Q4 FY26 Earnings Call Scheduled for May 14
Building on this strong quarter, CARE Ratings has scheduled its earnings call for Thursday, May 14, 2026, at 01:30 PM Indian Standard Time (IST). The call will focus on the company's financial results for the full fiscal year 2026 and the fourth quarter (Q4FY2026). Managing Director & Group CEO Mehul Pandya, along with the senior management team, will lead the discussion and address investor queries. This call offers investors a crucial opportunity to understand CARE Ratings' financial health, strategic priorities, and future outlook for FY2026. Management's commentary is expected to provide insight into performance drivers and the impact of recent business developments.
Expanding Roles in Credit and ESG
The company, a leading Indian credit rating agency since 1993 and part of the CareEdge Group, has recently expanded its role. SEBI appointed CARE Ratings to function as the Past Risk and Return Verification Agency (PaRRVA), a new regulatory role operational from May 4, 2026. Additionally, its subsidiary, CareEdge Global IFSC, has secured a license to provide ESG ratings. These developments are expected to shape the company's trajectory.
Market Concerns and Competitive Landscape
However, investors should be aware of certain market perceptions. As of March 2026, MarketsMOJO rated CARE Ratings stock as 'Sell', citing valuation metrics and technical indicators, despite acknowledging its 'good quality grade'. Past reputational challenges, such as those following the IL&FS incident, could also resurface as a concern. CARE Ratings operates within a competitive market alongside peers like CRISIL Ltd, the largest player with over 60% market share, and ICRA Ltd, which is affiliated with Moody's. While CRISIL leads in market share, CARE Ratings has historically offered a higher dividend yield. In the recently reported Q4 FY25, CARE Ratings' strong 76.4% year-over-year profit growth significantly outpaced ICRA's 19.1% and CRISIL's 7.5%.
Outlook and Investor Focus
Looking ahead, investors will want to hear management's detailed outlook and guidance for FY2026 performance. Key discussion points are likely to include the operationalization and impact of the new PaRRVA role and ESG rating services, as well as the company's strategy to address valuation concerns and market sentiment.